# KLF5

Source: https://onco.cc/targets/klf5/  
OnCo record `klf5` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KLF5 (Krueppel-like factor 5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Cervical cancer, Colorectal cancer and 1 more.

## Summary

Transcription factor that binds to GC box promoter elements. Activates the transcription of these genes.

CIViC holds 2 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes affected pathway 0.44, literature 0.99, genetic association 0.70, somatic mutation 0.80, animal model 0.46). IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma, Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: KLF transcription factor 5; Krueppel-like factor 5; BTEB2
- Tags: cancer-genes-wave
- Symbol: KLF5
- Class: transcription
- Biology: Transcription factor that binds to GC box promoter elements. Activates the transcription of these genes. Location: Nucleus (UniProt). Locus 13q22.1 (HGNC).
- Where found: Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA); Cervical cancer: IntOGen driver in 1 cohort (CESC); Colorectal cancer: Open Targets association 0.56 with colorectal cancer (MONDO_0005575); Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUSC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:6349: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6349
- UniProt Q13887: https://www.uniprot.org/uniprotkb/Q13887/entry
- NCBI Gene 688: https://www.ncbi.nlm.nih.gov/gene/688
- Ensembl ENSG00000102554: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102554

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/klf5.json